An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 5, 1998, Pages 535-539

  Ohshio, G ^a   Suwa, H ^b   Imamura, T ^b   Yamaki, K ^b   Tanaka, T ^b   Hashimoto, Y ^b   Imamura, M ^b  

^a Shiga Medical Center   (Japan)

^b NONE

Author keywords

Apoptosis; Bcl 2; P53; Pancreatic adenocarcinoma

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER GRADING; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031863603     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850172124     Document Type: Article

References (24)

1. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993;53:4701-14.
2. Hockenbery D, Nunez G, Millian C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
3. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
5. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-4.
6. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein; a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
7. Hurlimann J, Larrinaga B, Vala DLM. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426:163-8.
8. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
9. Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995;121:357-63.
10. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clesry K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
11. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
12. Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, Imamura T, et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997;40:649-53.
13. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359:552-4.
14. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79: 329-39.
15. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimichi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
16. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
17. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Can Res 1996;2:2015-22.
18. Gibson JB. Histological typing of tumours of the liver, biliary tract and pancreas. International histological classifications of the tumours. Geneva: WHO; 1978.
19. Klöppel G, Lingenthal G, Vonbulow M, Kern HF. Histological and fine structual features of pancreatic ductal adenocarcinomas in relation to growth and prognosis:studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985;9:841-56.
20. Ohshio G, Yoshioka H, Manabe T, Sakahara H, Yamabe H, Imamura M, et al. Expression of sialosyl-Tn antigen (monoclonal antibody MLS102 reactive) in normal tissues and malignant tumors of the digestive tract. J Cancer Res Clin Oncol 1994;29:325-30.
21. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88:6961-5.
22. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993;142:743-53.
23. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasis. Cancer 1994;73:2900-4.
24. Doussis IA, Pezzella F, Lane DP, Gatter KC, Phil D, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol 1993;99: 663-7.